SLC5A2 and type 2 diabetes mellitus: The most recently reported randomized controlled trial (RCT), the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial, showed that SGLT2 inhibitor use decreases the risk of cardiovascular events, compared with placebo [9].